TwinBeech Capital’s Arcus Biosciences RCUS Stock Holding History

TwinBeech Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-104,610	Closed	-$1.88M	–	867
2023 Q3	$1.88M	Buy	+104,610	New	+$2.1M	0.04%	419
2023 Q1	–	Sell	-129,642	Closed	-$2.68M	–	842
2022 Q4	$2.68M	Buy	+129,642	New	+$3.57M	0.05%	374
2022 Q2	–	Sell	-10,635	Closed	-$336K	–	692
2022 Q1	$336K	Buy	+10,635	New	+$356K	0.01%	421

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TwinBeech Capital's RCUS Position: Q4 2023 in Review

TwinBeech Capital sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 104,610 shares — an estimated $1.88M sold.

TwinBeech Capital first reported a position in RCUS in Q1 2022 and held it in 3 quarters. The position peaked at $2.68M in Q4 2022. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

TwinBeech Capital reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
TwinBeech Capital sold 104,610 Arcus Biosciences shares in Q4 2023, an estimated $1.88M.
TwinBeech Capital first reported a position in Arcus Biosciences in Q1 2022 and held it in 3 quarters.
TwinBeech Capital's Arcus Biosciences position peaked at $2.68M in Q4 2022.
185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on TwinBeech Capital's 13F filing for Q4 2023, filed 14 Feb 2024.